Clinical and genetic aspects of refractory forms of multiple myeloma development

Abstract

treatment of multiple myeloma has progressed significantly over the past years after the introduction of immunomodulation drugs and proteasome inhibitors. the median of patients survival has improved. All patients with multiple myeloma have relapses during a different time interval. the duration of the achieved remission in patients with a relapse of multiple myeloma becomes shorter with each subsequent case. the choice of regimen for relapse of multiple myeloma is very complex. it depends on a number of factors, including the previous induction regimen, the number of lines of the previous therapy, and the degree of aggression of relapse. the article is devoted to peculiarities of drug resistance formation in the first line therapy in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (c3435t)) and clinical-hematological, laboratory characteristics. The objective: to determine the peculiarities of drug resistance establishement in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (c3435t)) and clinical signes (hematological, laboratory characteristics) for predicting the effectiveness of treatment. Materials and methods. We conducted analysis of 68 clinically-laboratory indexes of 130 patients with multiple myeloma and their results of molecular-genetic research of deletion polymorphism of genes GSTT1, GSTM1, polymorphism А313G, C3435T genes GSTP1, MDR1. Results. it was determined that important predictors of development of refractory forms of multiple myeloma is allelic polymorphism of gene GSTM1 of patients, higher level α2-globulin and calcium in blood serum till the beginning of disease. Conclusions. implementation of predicative model taking into account polymorphism GstM1, of level α2-globulin and calcium in blood serum till the beginning of treatment raises efficiency of evaluation of individual prognosis of response on treatment.